Condition: Metastatic Breast Cancer · Metastatic Prostate Cancer · Sponsor: Ottawa Hospital Research Institute
The REaCT-CHRONO-MetBP Pilot study will compare morning and evening administration of endocrine-based therapy in metastatic breast and prostate cancers. Participants with metastatic breast or prostate cancer will be randomly placed in one of two groups: a morning group and an evening group. The group assignment will determine whether they take their endocrine therapy in the morning or the evening. The primary outcome of this pilot study is to evaluate the feasibility of study procedures in order to conduct a larger definitive trial in the future. The secondary outcomes include comparing quality of life, tolerability, and efficacy outcomes between the morning and evening groups for each of the two cancer cohorts (metastatic breast and prostate cancer).
This description comes directly from the study's public registry record.
Lisa Vandermeer, MSc · 613-737-7700 · lvandermeer@ohri.ca
Deanna Saunders, MSc · 613-737-7700 · dsaunders@ohri.ca
Always discuss trial participation with your own doctor first.
| Waterloo Regional Health Network | Kitchener, Ontario, Canada | Recruiting |
| The Ottawa Hospital Cancer Centre | Ottawa, Ontario, Canada | Recruiting |
| Saskatoon Cancer Centre | Saskatoon, Saskatchewan, Canada | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07252726